[go: up one dir, main page]

NO20012976L - Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament - Google Patents

Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament

Info

Publication number
NO20012976L
NO20012976L NO20012976A NO20012976A NO20012976L NO 20012976 L NO20012976 L NO 20012976L NO 20012976 A NO20012976 A NO 20012976A NO 20012976 A NO20012976 A NO 20012976A NO 20012976 L NO20012976 L NO 20012976L
Authority
NO
Norway
Prior art keywords
kqti
inhibitors
drug
channel
preparation
Prior art date
Application number
NO20012976A
Other languages
English (en)
Other versions
NO20012976D0 (no
Inventor
Uwe Gerlach
Joachim Hofmann
Hans Jochen Lang
Aguan Wei
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20012976D0 publication Critical patent/NO20012976D0/no
Publication of NO20012976L publication Critical patent/NO20012976L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20012976A 1998-12-17 2001-06-15 Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament NO20012976L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858253A DE19858253A1 (de) 1998-12-17 1998-12-17 Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
PCT/EP1999/009547 WO2000035429A1 (de) 1998-12-17 1999-12-07 Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden

Publications (2)

Publication Number Publication Date
NO20012976D0 NO20012976D0 (no) 2001-06-15
NO20012976L true NO20012976L (no) 2001-08-06

Family

ID=7891421

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012976A NO20012976L (no) 1998-12-17 2001-06-15 Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament

Country Status (24)

Country Link
US (2) US6335363B1 (no)
EP (1) EP1140042B1 (no)
JP (1) JP2002532412A (no)
KR (1) KR20010089574A (no)
CN (1) CN1170528C (no)
AR (1) AR021690A1 (no)
AT (1) ATE390130T1 (no)
AU (1) AU1559500A (no)
BR (1) BR9916190A (no)
CA (1) CA2355300A1 (no)
CZ (1) CZ20012125A3 (no)
DE (2) DE19858253A1 (no)
HK (1) HK1041647B (no)
HR (1) HRPK20010442B1 (no)
HU (1) HUP0200152A3 (no)
IL (1) IL143717A0 (no)
NO (1) NO20012976L (no)
NZ (1) NZ512408A (no)
PL (1) PL349511A1 (no)
RU (1) RU2238090C2 (no)
SK (1) SK8562001A3 (no)
TR (1) TR200101750T2 (no)
WO (1) WO2000035429A1 (no)
ZA (1) ZA200103620B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
EP2066179B1 (en) * 2006-09-01 2016-06-22 E. I. du Pont de Nemours and Company Formulations containing indoxacarb for local topical administration
ES2691893T3 (es) 2007-06-07 2018-11-29 Bayer Animal Health Gmbh Control de ectoparásitos
RU2364432C1 (ru) * 2008-03-21 2009-08-20 Олег Николаевич Моисеев Способ лечения глистных инвазий
US9968564B2 (en) 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
US20100310726A1 (en) 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US8859003B2 (en) * 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
AU2012275233A1 (en) 2011-06-30 2013-11-28 Genentech, Inc. Anti-c-met antibody formulations
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP2957557A1 (en) * 2014-06-17 2015-12-23 Novartis Tiergesundheit AG New compounds
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
US11485733B2 (en) * 2017-06-30 2022-11-01 Bayer Animal Health Gmbh Azaquinoline derivatives
MX2024008648A (es) 2022-01-12 2024-09-23 Denali Therapeutics Inc Formas cristalinas de (s)-5-bencil-n-(5-metil-4-oxo-2,3,4,5-tetrah idropirido [3,2- b][1,4]oxacepin-3-il)-4h-1,2,4-triazol-3-carboxam ida.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177083T1 (de) * 1993-11-29 1999-03-15 Merrell Pharma Inc Benzolsulfonyliminderivate als inhibitoren der il-1 wirkung
US5559026A (en) * 1994-10-31 1996-09-24 American Cyanamid Company Genes encoding a novel family of potassium channels
DE19504379A1 (de) * 1995-02-10 1996-08-14 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate sowie sie enthaltende pharmazeutische Präparate
EP0807629B1 (de) * 1996-05-15 2004-03-03 Aventis Pharma Deutschland GmbH Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
DE19706675A1 (de) 1997-02-20 1998-08-27 Hoechst Ag Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19707656A1 (de) 1997-02-26 1998-08-27 Hoechst Ag Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE19742508A1 (de) 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE19742509A1 (de) * 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE19748469A1 (de) * 1997-11-03 1999-05-06 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Benzopyranderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
HRP20010442A2 (en) 2002-06-30
NO20012976D0 (no) 2001-06-15
US6335363B1 (en) 2002-01-01
CN1330540A (zh) 2002-01-09
EP1140042A1 (de) 2001-10-10
US20020055537A1 (en) 2002-05-09
KR20010089574A (ko) 2001-10-06
IL143717A0 (en) 2002-04-21
DE59914712D1 (de) 2008-05-08
HK1041647B (zh) 2005-04-01
RU2238090C2 (ru) 2004-10-20
AR021690A1 (es) 2002-07-31
ATE390130T1 (de) 2008-04-15
HUP0200152A2 (hu) 2002-05-29
TR200101750T2 (tr) 2002-01-21
WO2000035429A1 (de) 2000-06-22
CZ20012125A3 (cs) 2001-09-12
JP2002532412A (ja) 2002-10-02
HRPK20010442B1 (en) 2003-10-31
CA2355300A1 (en) 2000-06-22
PL349511A1 (en) 2002-07-29
ZA200103620B (en) 2002-06-04
HK1041647A1 (en) 2002-07-19
AU1559500A (en) 2000-07-03
DE19858253A1 (de) 2000-06-21
BR9916190A (pt) 2001-09-11
NZ512408A (en) 2003-10-31
SK8562001A3 (en) 2001-12-03
HUP0200152A3 (en) 2003-01-28
EP1140042B1 (de) 2008-03-26
CN1170528C (zh) 2004-10-13

Similar Documents

Publication Publication Date Title
DE69935681D1 (de) Vorrichtungen zur Medikamentverabreichung
IS5760A (is) Meðferðarlegar bíarýl afleiður
ATE258928T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
ATE259796T1 (de) Respiratorisches syncytialvirus replikation inhibitoren
NO20005913D0 (no) Legemiddelsammensetning
IS6310A (is) Kínasólínafleiður til lækninga
EE03903B1 (et) Omeprasooli ravimvorm
EE9800194A (et) Uued valuvaigistava toimega ühendid
NO992339L (no) Farmasöytiske formuleringer
NO20005218D0 (no) Farmasøytisk aerosolpreparat
NO20040145L (no) Anvendelse av benzensulfonamidderivater for fremstilling av et medikament
NO20012976L (no) Anvendelse av inhibitorer av KQTI-kanalen for fremstilling av et medikament
MA26673A1 (fr) Composes pharmaceutiques
NO992692D0 (no) Nefadozon doseringsform
DK1466615T3 (da) Farmaceutisk præparat
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
ATE370728T1 (de) Antagonisten des gardos-kanals
NO20042393L (no) Polymorf av et farmakum
NO20014926D0 (no) Farmasöytiske forbindelser
EE200100611A (et) NOS inhibiitorite uued farmatseutilised kombinatsioonid
ATE283687T1 (de) Rapamycin-formulierungen zur oralen verabreichung
ID30032A (id) Formulasi farmasi
NO20013145D0 (no) Anvendelse av Na-H-bytter-inhibitorer for fremstilling av medikamenter
EE200100281A (et) Analgeetiline ravimkoostis
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application